Search results

Applying to the MSc Programme (60 ECTS) in Human Factors and Systems Safety is a two-stage process. Step 1 is the actual application to the programme. Step one includes providing personal data of the applicant, the submission of a personal letter, CV, copy of passport, as well as the approval of the applicant's line manager.Step 2 is where you validate your previous education credentials in order

https://www.humanfactors.lth.se/msc-programme-60ects/application-procedure - 2026-09-11

Below you can find three of our students sharing their experiences from their studies in our MSc (60 ECTS) programme. Anne-Mette Petri Øssur Hilduberg John Allspaw

https://www.humanfactors.lth.se/msc-programme-60ects/student-testimonials - 2026-09-11

In the video below our Programme Director Johan Bergström answers some of the most frequently asked questions. Some more FAQs Can I get a MSc degree if I do not have a Bachelor's? To qualify for the official Master of Science (MSc) degree (one year), a previous Bachelor of Science (BSc) or Bachelor of Arts (BA) degree is required and needs to be approved by the Swedish Council for Higher Education

https://www.humanfactors.lth.se/msc-programme-60ects/faq - 2026-09-11

MSc theses and student project reports published within the Human Factors & System Safety programme since 2010. MSc theses (LUP Student Papers)Student project reports (LUP Student Papers)

https://www.humanfactors.lth.se/msc-programme-60ects/publications - 2026-09-11

You can apply to one or several of our Learning laboratories. When applications are open there will be links to application forms. Critical thinking in safety – an introduction to the field11-15 January 2027On campus at Lund UniversityThe number of seats for the learning lab are limited and provided on a first come, first served basis. Please register here:January learning lab-registration (extern

https://www.humanfactors.lth.se/learning-laboratories/upcoming-learning-laboratories - 2026-09-11

Participation costs SEK 20 000 (plus VAT where applicable) for each Learning laboratory. This does not include cost for the books that we may recommend you to read, nor the cost of travel or accommodation. Swedish law does not allow students to pay for their own education, so we will need information from your employer or other applicable sponsor for your participation in the Learning laboratory.Y

https://www.humanfactors.lth.se/learning-laboratories-human-factors-and-system-safety/tuition-fee-and-entry-requirements - 2026-09-11

Johan Bergström Programme Director Email: johan [dot] bergstrom [at] risk [dot] lth [dot] se Mobile: +46 46 222 08 80 Johan Bergström's profile in Lund University's Research Portal If you have questions about the MSc programme or the Learning laboratories, you're very welcome to contact me!

https://www.humanfactors.lth.se/contact - 2026-09-11

Lund University is pleased to offer a complete Masters of Science programme (60 ECTS) for professionals and practitioners in Human Factors and System Safety. IntroductionThe programme starts with a week of intensive lectures and orientation in Lund, the rest you can do on-line, in two years. The MSc is concluded with a thesis. With no prior Bachelor's degree, you can still take the entire MSc prog

https://www.humanfactors.lth.se/msc-programme-60ects - 2026-09-11

Our understanding of accidents, risk and safety is changing. We no longer see human error as cause, but as a symptom. We recognize the exciting possibilities of systems thinking for accident analysis and organizational improvement. We are shifting from reliability to resilience and the enhancement of adaptive capacity. We look for new relationships between stakeholders to create forms of accountab

https://www.humanfactors.lth.se/learning-laboratories - 2026-09-11

Gunilla Westergren-Thorsson Director Email: gunilla [dot] westergren-thorsson [at] med [dot] lu [dot] se Telephone: +46 46 222 86 95 Mobile: +46 70 594 63 60 Kristian Pietras Co-director Email: kristian [dot] pietras [at] med [dot] lu [dot] se Telephone: +46 46 222 05 80 Lisa Rydén Clinical Co-Director Email: lisa [dot] ryden [at] med [dot] lu [dot] se Lisa Karlsson Scientific Communicator and coo

https://www.wcmm.lu.se/wallenberg-center-molecular-medicine-lund/management - 2026-09-11

What is WCMM Fusion 2025?This exhibition invites you to explore the fascinating intersection of science and art through stunning medical images created by the talented WCMM scientists. Each artwork tells a unique story of ongoing research, how it contributes to advancing scientific knowledge or addresses a specific medical need, and how far the research is with the goal of ultimately impacting cli

https://www.wcmm.lu.se/whats/wcmm-fusion-2025-where-science-meets-art - 2026-09-11

Postdoctoral program designed to foster cutting-edge translational research WCMM Lund is taking a significant step forward in training the new generation of young international, highly qualified postdoc candidates within the field of regenerative medicine with the launch of its IGNITE Postdoc Fellow Program. This initiative, funded by the Wallenberg Foundation, aims to support postdoctoral researc

https://www.wcmm.lu.se/ignite-postdoc-fellow-program - 2026-09-11

Cancer is a worldwide health challenge leading to increased mortality and diminishing quality of life of millions of people. In recent years, immunotherapy has transformed cancer treatment, but targeting effectively refractory solid tumours remains a challenge due to poor T cell activation. Downregulation of antigen presentation pathways and lack of professional antigen presenting cells in the tum

https://www.wcmm.lu.se/driving-tumor-antigen-presentation-rna-mediated-transdifferentiation - 2026-09-11

The emergence of induced pluripotent stem cells (iPS) has offered unprecedented opportunities in developmental biology and regenerative medicine. Generated from patient cells, iPS maintains their genetic features, allowing deciphering healthy or pathological processes in a personalized fashion. Applied to hematopoiesis, this technology holds enormous promises towards generating transplantable hema

https://www.wcmm.lu.se/human-ossicles-ips-hsc-development-and-leukemia-modeling - 2026-09-11

Introduction | Chronic inflammation in autoimmune diseases is driven by resident T cells and a breakdown in immune tolerance. Systemic factors often complicate the study of local antigen presentation; however, juvenile idiopathic arthritis (JIA) provides a unique model due to its joint-specific inflammation. While innate immune-driven T-cell activation has been observed in JIA, the roles of autoan

https://www.wcmm.lu.se/local-breach-tolerance-understanding-process-chronicity-autoimmune-disease - 2026-09-11

Why only certain animal species can regenerate complex structures remains an important and open question. Technological advances have now opened the door to studying the molecular mechanisms of highly regenerative species, like salamanders. A unique aspect of regeneration in these species is that fully differentiated cells are coaxed to re-enter the cell cycle. This reentry is typically blocked by

https://www.wcmm.lu.se/elucidating-underlying-mechanisms-cell-cycle-regulation-limb-regeneration - 2026-09-11

Multi-drug resistant bacterial infections, such as Pseudomonas aeruginosa represent a significant global health care burden and disproportionately impact patients who are immuno-comprised, which make them more susceptible to opportunistic pathogens. These infections impact a broad range of patients, including those with chronic diseases such as diabetes, cancer, organ transplant recipients, and th

https://www.wcmm.lu.se/apical-out-human-airway-organoids-chip-derived-ipscs-studying-bacterial-infections - 2026-09-11

Lung transplantation is currently the only treatment option for end-stage lung disease. Despite procedural improvements, primary graft dysfunction (PGD) remains a leading cause of early mortality and chronic allograft dysfunction, leading to poor long-term survival rates. Mesenchymal stem/stromal cell (MSC) based therapies have the potential to ameliorate injured donor lungs and to improve the res

https://www.wcmm.lu.se/advanced-engineered-msc-therapies-lung-transplantation - 2026-09-11

RNA based therapeutics, e.g., siRNA, antisense, mRNA- and CRISPR-based drugs, are a novel class of drugs that that are potential ideal precision drugs for oncology given their highly specific and targeted nature. However, cytosolic delivery remains the major obstacle to macromolecular RNA drug development.In my (Anders Wittrup) lab we have developed several new techniques both for detection and qu

https://www.wcmm.lu.se/discovery-and-characterization-cell-biological-barriers-therapeutic-rna-delivery - 2026-09-11

Back to news archive2017-11-30: Grants awarded from the Swedish Research Council (VR) and the Swedish Cancer Society (Cancerfonden)Congratulations to the following WCMM researchers who have recently received grants:ANJA MEISSNER, who received 800 tKr/year (2018-2020) from the Swedish Research Council (VR-M) for the project “The communication between Sphingosine-1-phosphate signaling and the Renin-

https://www.wcmm.lu.se/grant-award - 2026-09-11